The role of nasal and gut microbiota in allergic rhinitis: immunomodulation and therapeutic prospects
Abstract
Allergic rhinitis (AR) is a prevalent immunoglobulin E (IgE)-mediated inflammatory disorder of the nasal mucosa that imposes substantial global health and socioeconomic burdens. The pathogenesis of AR involves complex interactions among epithelial barrier dysfunction, immune dysregulation, and environmental factors. Emerging evidence underscores the critical role of the human microbiota, particularly communities residing in the nasal cavity and gut, in modulating immune homeostasis and susceptibility to AR. Early-life microbial exposure profoundly shapes initial microbiota colonization. Observational and longitudinal studies associate nasal and gut dysbiosis with impaired immune tolerance and an increased risk of AR, although the causal direction of these associations remains incompletely established. At a mechanistic level, microbial communities may influence AR through short-chain fatty acids and other metabolites, epithelial barrier integrity, and an integrated innate/adaptive network comprising type 2 innate lymphoid cells, dendritic cell subsets, Th 1, Th2, Th17, and regulatory T cells, together with epigenetic regulation. Among microbiota-targeted interventions, selected probiotic strains and bacterial lysates show modest, strain- and regimen-specific benefits in some randomized trials, whereas fecal microbiota transplantation remains experimental in AR, with current support extrapolated from other conditions and preclinical models. This review synthesizes current insights into microbiota-AR interactions and their underlying mechanisms, explicitly distinguishing human, preclinical, and mechanistic evidence, and critically appraises the therapeutic potential and limitations of microbiota-targeted strategies for AR prevention and treatment.
Related
- Improving allergic rhinitis symptoms through nutrition as an adjunct: a systematic review and meta-analysis on the efficacy of dietary supplements
- Association of Score for Allergic Rhinitis with Serum Total IgE and Clinical Characteristics in Patients with Allergic Rhinitis
- Environmental Ligands of the Aryl Hydrocarbon Receptor in Allergic Rhinitis: Immune and Neuroimmune Mechanisms
- Low-density neutrophil subsets in allergic rhinitis: heterogeneity and an emerging hypothesis for the non-type 2 endotype
- Evidence-to-Recommendation Framework for 2026 ACE Clinical Guideline on allergic rhinitis — diagnosis and management
BibTeX
@article{yan2026role,
title = {{The role of nasal and gut microbiota in allergic rhinitis: immunomodulation and therapeutic prospects}},
author = {Yali Yan and Liang Bao and Xiao Chen and Huiying Xiao},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1984960},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1984960},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The role of nasal and gut microbiota in allergic rhinitis: immunomodulation and therapeutic prospects
AU - Yali Yan
AU - Liang Bao
AU - Xiao Chen
AU - Huiying Xiao
PY - 2026
DA - 2026/10/30
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1984960
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1984960
AB - Allergic rhinitis (AR) is a prevalent immunoglobulin E (IgE)-mediated inflammatory disorder of the nasal mucosa that imposes substantial global health and socioeconomic burdens. The pathogenesis of AR involves complex interactions among epithelial barrier dysfunction, immune dysregulation, and environmental factors. Emerging evidence underscores the critical role of the human microbiota, particularly communities residing in the nasal cavity and gut, in modulating immune homeostasis and susceptibility to AR. Early-life microbial exposure profoundly shapes initial microbiota colonization. Observational and longitudinal studies associate nasal and gut dysbiosis with impaired immune tolerance and an increased risk of AR, although the causal direction of these associations remains incompletely established. At a mechanistic level, microbial communities may influence AR through short-chain fatty acids and other metabolites, epithelial barrier integrity, and an integrated innate/adaptive network comprising type 2 innate lymphoid cells, dendritic cell subsets, Th 1, Th2, Th17, and regulatory T cells, together with epigenetic regulation. Among microbiota-targeted interventions, selected probiotic strains and bacterial lysates show modest, strain- and regimen-specific benefits in some randomized trials, whereas fecal microbiota transplantation remains experimental in AR, with current support extrapolated from other conditions and preclinical models. This review synthesizes current insights into microbiota-AR interactions and their underlying mechanisms, explicitly distinguishing human, preclinical, and mechanistic evidence, and critically appraises the therapeutic potential and limitations of microbiota-targeted strategies for AR prevention and treatment.
SN - 1664-3224
ER -